MEDPACE HOLDINGS INC (MEDP) Fundamental Analysis & Valuation
NASDAQ:MEDP • US58506Q1094
466.79 USD
-11.75 (-2.46%)
At close: Mar 10, 2026
466.79 USD
0 (0%)
After Hours: 3/10/2026, 6:31:14 PM
This MEDP fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
We assign a fundamental rating of 7 out of 10 to MEDP. MEDP was compared to 57 industry peers in the Life Sciences Tools & Services industry. Both the health and profitability get an excellent rating, making MEDP a very profitable company, without any liquidiy or solvency issues. MEDP is not overvalued while it is showing excellent growth. This is an interesting combination. This makes MEDP very considerable for growth and quality investing!
1. MEDP Profitability Analysis
1.1 Basic Checks
- In the past year MEDP was profitable.
- In the past year MEDP had a positive cash flow from operations.
- MEDP had positive earnings in each of the past 5 years.
- Each year in the past 5 years MEDP had a positive operating cash flow.
1.2 Ratios
- MEDP has a Return On Assets of 22.84%. This is amongst the best in the industry. MEDP outperforms 98.25% of its industry peers.
- With an excellent Return On Equity value of 98.27%, MEDP belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
- With an excellent Return On Invested Capital value of 71.19%, MEDP belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
- Measured over the past 3 years, the Average Return On Invested Capital for MEDP is significantly above the industry average of 11.85%.
- The 3 year average ROIC (49.20%) for MEDP is below the current ROIC(71.19%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 22.84% | ||
| ROE | 98.27% | ||
| ROIC | 71.19% |
ROA(3y)19.71%
ROA(5y)17.64%
ROE(3y)65.94%
ROE(5y)56.06%
ROIC(3y)49.2%
ROIC(5y)40.37%
1.3 Margins
- MEDP has a better Profit Margin (17.83%) than 85.96% of its industry peers.
- MEDP's Profit Margin has improved in the last couple of years.
- MEDP has a better Operating Margin (21.14%) than 89.47% of its industry peers.
- In the last couple of years the Operating Margin of MEDP has grown nicely.
- The Gross Margin of MEDP (30.06%) is worse than 73.68% of its industry peers.
- In the last couple of years the Gross Margin of MEDP has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 21.14% | ||
| PM (TTM) | 17.83% | ||
| GM | 30.06% |
OM growth 3Y3.46%
OM growth 5Y3.23%
PM growth 3Y2.01%
PM growth 5Y2.64%
GM growth 3Y0.5%
GM growth 5Y-0.03%
2. MEDP Health Analysis
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), MEDP is creating value.
- Compared to 1 year ago, MEDP has less shares outstanding
- The number of shares outstanding for MEDP has been reduced compared to 5 years ago.
- MEDP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- MEDP has an Altman-Z score of 7.01. This indicates that MEDP is financially healthy and has little risk of bankruptcy at the moment.
- MEDP's Altman-Z score of 7.01 is amongst the best of the industry. MEDP outperforms 91.23% of its industry peers.
- There is no outstanding debt for MEDP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 7.01 |
ROIC/WACC6.53
WACC10.9%
2.3 Liquidity
- A Current Ratio of 0.74 indicates that MEDP may have some problems paying its short term obligations.
- MEDP has a Current ratio of 0.74. This is amonst the worse of the industry: MEDP underperforms 94.74% of its industry peers.
- MEDP has a Quick Ratio of 0.74. This is a bad value and indicates that MEDP is not financially healthy enough and could expect problems in meeting its short term obligations.
- MEDP has a worse Quick ratio (0.74) than 92.98% of its industry peers.
- MEDP does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.74 | ||
| Quick Ratio | 0.74 |
3. MEDP Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an impressive 21.14% over the past year.
- MEDP shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 31.30% yearly.
- MEDP shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 19.97%.
- The Revenue has been growing by 22.27% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)21.14%
EPS 3Y27.86%
EPS 5Y31.3%
EPS Q2Q%27.25%
Revenue 1Y (TTM)19.97%
Revenue growth 3Y20.12%
Revenue growth 5Y22.27%
Sales Q2Q%32.03%
3.2 Future
- The Earnings Per Share is expected to grow by 10.52% on average over the next years. This is quite good.
- Based on estimates for the next years, MEDP will show a quite strong growth in Revenue. The Revenue will grow by 9.03% on average per year.
EPS Next Y13.94%
EPS Next 2Y12.47%
EPS Next 3Y12.37%
EPS Next 5Y10.52%
Revenue Next Year11.75%
Revenue Next 2Y9.61%
Revenue Next 3Y9.54%
Revenue Next 5Y9.03%
3.3 Evolution
- Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. MEDP Valuation Analysis
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 30.51, MEDP can be considered very expensive at the moment.
- 61.40% of the companies in the same industry are more expensive than MEDP, based on the Price/Earnings ratio.
- MEDP's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 26.25.
- Based on the Price/Forward Earnings ratio of 26.78, the valuation of MEDP can be described as expensive.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of MEDP indicates a somewhat cheap valuation: MEDP is cheaper than 63.16% of the companies listed in the same industry.
- MEDP's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 24.39.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.51 | ||
| Fwd PE | 26.78 |
4.2 Price Multiples
- 61.40% of the companies in the same industry are more expensive than MEDP, based on the Enterprise Value to EBITDA ratio.
- Based on the Price/Free Cash Flow ratio, MEDP is valued cheaper than 82.46% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 19.43 | ||
| EV/EBITDA | 23.24 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- MEDP has an outstanding profitability rating, which may justify a higher PE ratio.
- MEDP's earnings are expected to grow with 12.37% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.19
PEG (5Y)0.97
EPS Next 2Y12.47%
EPS Next 3Y12.37%
5. MEDP Dividend Analysis
5.1 Amount
- MEDP does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
MEDP Fundamentals: All Metrics, Ratios and Statistics
466.79
-11.75 (-2.46%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-09 2026-02-09/amc
Earnings (Next)04-20 2026-04-20/amc
Inst Owners84.9%
Inst Owner Change-2.17%
Ins Owners0.51%
Ins Owner Change-4.97%
Market Cap13.25B
Revenue(TTM)2.53B
Net Income(TTM)451.12M
Analysts70.53
Price Target497.46 (6.57%)
Short Float %5.69%
Short Ratio3.99
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.54%
Min EPS beat(2)7.52%
Max EPS beat(2)9.56%
EPS beat(4)4
Avg EPS beat(4)9.37%
Min EPS beat(4)2.57%
Max EPS beat(4)17.84%
EPS beat(8)8
Avg EPS beat(8)12.36%
EPS beat(12)11
Avg EPS beat(12)11.35%
EPS beat(16)15
Avg EPS beat(16)14.34%
Revenue beat(2)2
Avg Revenue beat(2)0.84%
Min Revenue beat(2)0.75%
Max Revenue beat(2)0.93%
Revenue beat(4)4
Avg Revenue beat(4)3.88%
Min Revenue beat(4)0.75%
Max Revenue beat(4)9.78%
Revenue beat(8)4
Avg Revenue beat(8)0.78%
Revenue beat(12)7
Avg Revenue beat(12)1.31%
Revenue beat(16)10
Avg Revenue beat(16)1.28%
PT rev (1m)-10.76%
PT rev (3m)-9.07%
EPS NQ rev (1m)1.41%
EPS NQ rev (3m)2.01%
EPS NY rev (1m)3.71%
EPS NY rev (3m)3.81%
Revenue NQ rev (1m)2.43%
Revenue NQ rev (3m)2.44%
Revenue NY rev (1m)-0.21%
Revenue NY rev (3m)-0.17%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.51 | ||
| Fwd PE | 26.78 | ||
| P/S | 5.24 | ||
| P/FCF | 19.43 | ||
| P/OCF | 18.57 | ||
| P/B | 28.86 | ||
| P/tB | N/A | ||
| EV/EBITDA | 23.24 |
EPS(TTM)15.3
EY3.28%
EPS(NY)17.43
Fwd EY3.73%
FCF(TTM)24.03
FCFY5.15%
OCF(TTM)25.13
OCFY5.38%
SpS89.16
BVpS16.18
TBVpS-8.34
PEG (NY)2.19
PEG (5Y)0.97
Graham Number74.62
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 22.84% | ||
| ROE | 98.27% | ||
| ROCE | 84.68% | ||
| ROIC | 71.19% | ||
| ROICexc | 333.94% | ||
| ROICexgc | N/A | ||
| OM | 21.14% | ||
| PM (TTM) | 17.83% | ||
| GM | 30.06% | ||
| FCFM | 26.95% |
ROA(3y)19.71%
ROA(5y)17.64%
ROE(3y)65.94%
ROE(5y)56.06%
ROIC(3y)49.2%
ROIC(5y)40.37%
ROICexc(3y)169.04%
ROICexc(5y)114.84%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)58.52%
ROCE(5y)48.87%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y101.11%
ROICexc growth 5Y74.12%
OM growth 3Y3.46%
OM growth 5Y3.23%
PM growth 3Y2.01%
PM growth 5Y2.64%
GM growth 3Y0.5%
GM growth 5Y-0.03%
F-Score7
Asset Turnover1.28
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 111.49% | ||
| Cap/Sales | 1.24% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 126.67% | ||
| Profit Quality | 151.15% | ||
| Current Ratio | 0.74 | ||
| Quick Ratio | 0.74 | ||
| Altman-Z | 7.01 |
F-Score7
WACC10.9%
ROIC/WACC6.53
Cap/Depr(3y)125.21%
Cap/Depr(5y)134.9%
Cap/Sales(3y)1.64%
Cap/Sales(5y)1.98%
Profit Quality(3y)144.35%
Profit Quality(5y)141.17%
High Growth Momentum
Growth
EPS 1Y (TTM)21.14%
EPS 3Y27.86%
EPS 5Y31.3%
EPS Q2Q%27.25%
EPS Next Y13.94%
EPS Next 2Y12.47%
EPS Next 3Y12.37%
EPS Next 5Y10.52%
Revenue 1Y (TTM)19.97%
Revenue growth 3Y20.12%
Revenue growth 5Y22.27%
Sales Q2Q%32.03%
Revenue Next Year11.75%
Revenue Next 2Y9.61%
Revenue Next 3Y9.54%
Revenue Next 5Y9.03%
EBIT growth 1Y19.71%
EBIT growth 3Y24.28%
EBIT growth 5Y26.22%
EBIT Next Year16.28%
EBIT Next 3Y12.32%
EBIT Next 5Y10.93%
FCF growth 1Y19.15%
FCF growth 3Y24.75%
FCF growth 5Y24.56%
OCF growth 1Y17.15%
OCF growth 3Y22.49%
OCF growth 5Y22.49%
MEDPACE HOLDINGS INC / MEDP FAQ
What is the fundamental rating for MEDP stock?
ChartMill assigns a fundamental rating of 7 / 10 to MEDP.
Can you provide the valuation status for MEDPACE HOLDINGS INC?
ChartMill assigns a valuation rating of 5 / 10 to MEDPACE HOLDINGS INC (MEDP). This can be considered as Fairly Valued.
What is the profitability of MEDP stock?
MEDPACE HOLDINGS INC (MEDP) has a profitability rating of 9 / 10.
What are the PE and PB ratios of MEDPACE HOLDINGS INC (MEDP) stock?
The Price/Earnings (PE) ratio for MEDPACE HOLDINGS INC (MEDP) is 30.51 and the Price/Book (PB) ratio is 28.86.
How financially healthy is MEDPACE HOLDINGS INC?
The financial health rating of MEDPACE HOLDINGS INC (MEDP) is 8 / 10.